Recent VXRT News
- Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need • GlobeNewswire Inc. • 10/15/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/08/2024 08:06:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 08:05:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 09:20:22 PM
- Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 09/30/2024 08:12:22 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/30/2024 12:00:00 PM
- Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:16:00 PM
- Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:01:00 PM
- Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 • GlobeNewswire Inc. • 08/02/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 10:10:10 AM
- Vaxart Provides Business Update • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 10:02:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:03:24 AM
- Vaxart Announces $40 Million Underwritten Offering of Common Stock • GlobeNewswire Inc. • 06/13/2024 11:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:26:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:36:53 PM
- Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 06/13/2024 08:15:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:38:42 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/23/2024 08:01:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM